[Comparative efficacy of intradermal and intramuscular active immunization against hepatitis B with a recombinant vaccine. Preliminary results].
Preliminary results of a prospective, comparative and randomized study on 119 sero-negative volunteers with increased risk to acquire hepatitis B, aimed to evaluate the comparative efficacy of a recombinant vaccine administered either intramuscularly or intradermally, are discussed. A short vaccination schedule of three consecutive doses given on months 0, 1 and 2 was used. Distribution by sex and age for both groups was similar. Seroconversion and seroprotection rates were comparable (96% and 96% Vs. 98% and 93%, respectively). The geometric mean titre of anti-HBsAg in individuals immunized via I.M. (155 IU/L) was significantly higher to that of the I.D. group (71 IU/L). On the other hand, the rate of good response (> 100 IU/L) was also higher in the I.M. group (67% Vs. 39%). The percentage of good responder in women was consistently higher than in men for both groups (75% Vs. 13%, respectively). In 68 vaccinees, samples were obtained one year later. The levels of anti-HBsAg and the anamnesic response after a booster of the vaccine are currently being assayed.
Torres
J R
JR
Instituto de Medicina Tropical, Universidad Central de Venezuela.
de Marquez
M L
ML
Gonzalez
A
A
Ramirez
V
V
Martinez
N
N
Lecuna
V
V
D000328:Adult; D005260:Female; D006509:Hepatitis B / Q000276:immunology* / Q000517:prevention & control; D006514:Hepatitis B Surface Antigens / Q000008:administration & dosage; D017325:Hepatitis B Vaccines / Q000008:administration & dosage* / Q000276:immunology; D006801:Humans; D007115:Immunization Schedule; D007271:Injections, Intradermal; D007273:Injections, Intramuscular; D008297:Male; D011446:Prospective Studies; D014614:Vaccines, Synthetic / Q000008:administration & dosage* / Q000276:immunology
D006514:Hepatitis B Surface Antigens; D017325:Hepatitis B Vaccines; D014614:Vaccines, Synthetic
Eficacia comparativa de las vías intradérmica e intramuscular en la inmunización activa contra la hepatitis B con una vacuna recombinante. Resultados preliminares.